Alzheimer's disease (AD) is a neurodegenerative dementia condition in which the irreversible loss of neurons leads to progressive deterioration in cognitive function. AD is widely thought to be caused by protein abnormalities, the build-up of β-amyloid (Aβ) in extracellular plaques and the disintegration of tau protein in intracellular neurofibrillary tangles (NFTs) 1, 2 . Substantial evidence indicates that the excessive production of Aβ peptides and the following aggregation to yield Aβ plaques have definite correlates with the initiation of AD pathology. Thus, imaging of Aβ plaques with non-invasive techniques including positron emission tomography (PET) and single-photon emission computed tomography (SPECT) now may aid in tracking amyloid pathology and achieving presymptomatic identification of AD patients 3 .
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Alzheimer's disease (AD) is a neurodegenerative dementia condition in which the irreversible loss of neurons leads to progressive deterioration in cognitive function. AD is widely thought to be caused by protein abnormalities, the build-up of β-amyloid (Aβ) in extracellular plaques and the disintegration of tau protein in intracellular neurofibrillary tangles (NFTs) 1, 2 . Substantial evidence indicates that the excessive production of Aβ peptides and the following aggregation to yield Aβ plaques have definite correlates with the initiation of AD pathology. Thus, imaging of Aβ plaques with non-invasive techniques including positron emission tomography (PET) and single-photon emission computed tomography (SPECT) now may aid in tracking amyloid pathology and achieving presymptomatic identification of AD patients 3 .
In recent decades, researchers have manipulated the Congo red (CR) and Thioflavin T (ThT) pharmacophores to make suitable imaging agents targeted to Aβ plaques. The result of this work is that several Aβ-selective PET 6 were approved by the U.S. FDA over the last two years ( Fig. 1 ). However, as more SPECT scanners have been installed in hospitals, it would be more practical to design SPECT imaging agents. [ 123 I]IMPY, an improved ThT derivative, has been well-characterized and tested in preclinical trials. The signal-to-noise ratio of this compound for Aβ labeling was found to be less than satisfactory, possibly due to its high lipophilicity and in vivo instability 7, 8 . Recently, we have transitioned away from these well-known Aβ-selective ligands that bear extended π -conjugated systems in rigid flat molecules. A class of 125 I-labeled flexible benzyloxybenzene derivatives without highly rigid planarity have been synthesized and screened as radiotracers for SPECT imaging of Aβ plaques 9 . The most interesting compound ([ 125 I]4) displayed strong labeling of Aβ plaques on brain sections from AD patients and transgenic (Tg) mice, good blood-brain barrier (BBB) penetration, rapid washout from the normal brain and satisfactory in vitro and in vivo biostability. In addition, two statistically reliable three-dimensional quantitative structure− activity relationship (3D-QSAR) models, comparative molecular field analysis (CoMFA) and comparative molecular similarity indices analysis (CoMSIA), were constructed to aid in the design of new potent Aβ imaging agents. Based on the benzyloxybenzene scaffold, we designed two ligands (7a and 12a) with fluoroethoxy groups and iodides para-substituted at both benzene rings, which could be labeled with either 18 F or 125 I radioisotopes to give radioactive products with identical structures. These new ligands are expected to be both PET (   18   F) and  SPECT (   123   I/ 125 I) active, enabling both imaging modes using a single ligand (Fig. 1 ). These two ligands were separately 18 F and 125 I labeled and subjected to different in vitro and in vivo assays to assess their usefulness as PET/SPECT imaging agents targeted to Aβ plaques.
Results
Computational studies. To evaluate the binding affinities of the newly designed dual imaging ligands to Aβ fibers before conducting synthetic and biological experiments, molecular docking and K i predictions were performed 9 . Geometry optimizations were executed at the B3LYP/6-31G and 3-21G levels in the water phase. The optimized geometries of 7a and 12a were non-planar, resembling other recently reported benzyloxybenzene ligands ( Figure S1a ,b in Supplementary information). Similar results were obtained in the docking simulations. As shown in Fig. 2 , ligands 7a and 12a were both predicted to insert into the hydrophobic Val18_Phe20 channel of Aβ fibers, the same as compound 4 and the well-studied IMPY molecule. To fit within the binding pocket, both ligands rotated into nearly flat conformations. 7a and 12a were predicted to bind tightly to Aβ fibers and compete well against compound 4 and IMPY. Previously constructed 3D-QSAR models successfully predicted the K i values of 7a and 12a. As shown in Fig. 3d Chemistry. Figure 4 outlines the synthesis of the desired benzyloxybenzene derivatives 7a, 12a and their precursors. The phenols 6a and 6b used to prepare 7a-7c were acquired by coupling 1-bromo-2-fluoroethane or 2-chloroethanol with the hydroxy group of 4-(benzyloxy)phenol, followed by debenzylation with Pd/C under a hydrogen atmosphere. Coupling 1-bromo-2-fluoroethane or 1,2-dibromoethane with the hydroxy group of 4-hydroxybenzaldehyde yielded 9a and 9b. Then, 9a and 9b were reduced with NaBH 4 to produce the corresponding benzyl alcohols 10a and 10b in high yields of 91.1% and 95.8%, respectively. Conversion of 10a and 10b to benzyl bromides 11a and 11b were achieved by bromination using PBr 3 in high yields of 95.0% and 99.0%, respectively. The benzyloxybenzene backbone was formed in a base-catalyzed S N 2 reaction between para-substituted benzyl bromides and corresponding phenols in yields greater than 70%. The tributyltin precursors 8b and 13b for 125 I labeling were obtained using a bromo to tributyltin exchange reaction catalyzed by Pd(PPh 3 ) 4 from the corresponding bromo compounds 7c and 12c in yields of 30.4% and 25.1%, respectively. The tosylate precursor 8a for 18 F labeling was prepared through the common method of converting the free hydroxy group of 7b into tosylate with TsCl in a yield of 40.6%. An attempt to synthesize the tosylate precursor 13a from the hydroxyethoxy derivative 2-(4-((4-iodophenoxy)methyl)phenoxy) ethanol, failed due to the difficulty in obtaining the key intermediate, 2-(4-(bromomethyl)phenoxy)ethanol. Thus, an alternative method was adopted in which the bromo group was converted into tosylate using silver p-toluenesulfonate, providing the tosylate precursor 13a from the bromoethoxy substituted compound 12b in a yield of 57.0%.
Single crystals of 12a were obtained by slow evaporation from ethyl acetate at room temperature, and its structure was then elucidated using the SHELXL97 program. The X-ray crystallographic structure conformed well to the geometries of the optimized structure with a root mean square deviation (RMSD) of 0.19 Å, which was calculated using VMD 1.9.1 software after alignment ( Figure S1 in Supplementary information). The small RMSD value suggested that the geometric optimizations were successful. Therefore, it is valid to use the optimized structures for the QSAR and molecular docking calculations.
In vitro binding assay using Aβ aggregates. The binding affinities of 7a and 12a to Aβ 42 aggregates were quantitatively evaluated by a competition binding assay using [
125 I]4 as the competing radio-ligand according to conventional methods 10 . Ligands 7a and 12a inhibited the binding of [
with K i values of 19.5 ± 7.1 nM and 23.9 ± 7.9 nM, respectively, which were slightly better than that of IMPY (K i = 32.2 ± 2.1 nM) and PIB (K i = 38.8 ± 2.6 nM) in the identical assay (Fig. 3) . These values suggest that 7a and 12a have excellent binding abilities and can efficiently label Aβ plaques in the AD brain. The actual binding affinities agreed well with values predicted by the CoMFA and CoMSIA models, with pK i values deviating by less than 0.5 log unit. This satisfactory result strongly validated the reliability of the established 3D-QSAR models. This ability to accurately predict the binding activities of new benzyloxybenzene derivatives will be of great help for future efforts to design new potent Aβ imaging agents.
Radiolabeling.

125
I was introduced using corresponding tributyltin precursors via an iododestannylation reaction, providing [ F-labeled radiotracers in a radiochemical purity of greater than 98%. Small deviations of retention times between these radiotracers and corresponding non-radioactive compounds in co-injection HPLC analysis successfully verified their radiochemical identities (Table S2 , Figure S2 in Supplementary information).
In vitro autoradiography. To characterize the high specific binding abilities of these dual radiolabeled imaging agents to Aβ plaques, in vitro autoradiography was performed on brain sections from AD patients and Tg model mice. As shown in Fig. 5a ,e,i,m,c,g,k,o, clusters of hot spots accumulated in the cerebral cortex sections of AD patient and Tg mouse brains, and the locations coincided precisely with the fluorescent specks observed after staining with Thioflavin-S (ThS), a conventional dye usually used to stain Aβ plaques. In contrast, healthy human and wild-type mouse brain sections displayed no significant accumulation of radioactivity (Fig. 5b,f,j,n,d ,h,l,p). This result reflected the high specific binding of 7a and 12a in the competition binding assay, and proved the feasibility and practicality of using Table S3 in Supplementary information implied that the four radiolabeled tracers have slightly higher lipophilicity but are still able to cross the BBB.
Histograms of brain and intestine uptake were presented in Fig. 6 for comparison, while detailed data concerning the in vivo biodistribution in normal ICR mice were collected in Table S3 in Supplementary information. All four radiolabeled tracers exhibited high initial brain uptake at 2 min post-injection F]12a), resulting in brain 2 min /brain 60 min ratios as low as 1.8 and 1.6, respectively. Meanwhile, radioactivity in the blood, heart, spleen and muscle all decreased slowly over time, and the uptake levels remained appreciable at 60 min post-injection. By closely comparing the initial uptakes, we found that less [ F]12a exhibited no significant concentration in the intestine, maintaining nearly constant radioactivity values of approximately 8% ID/g through the whole investigative time period. Biodistribution studies of 18 F-labeled 7a and 12a implied that the majority of radioactive compounds were not excreted by the normal mice and remained in circulation, resulting in relatively slower washout rates from the brain.
To further assess the pharmacokinetics of these two couple of radiolabeled benzyloxybenzenes, following dynamic PET/CT and SPECT/CT scans were conducted in normal ICR mice. High contrast PET and SPECT images implied that all the four radiolabeled benzyloxybenzenes can penetrate the BBB to a great degree and washout from the normal brain regions (Fig. 7a) showed that the radioactivity mainly accumulated in the brain, heart and liver at the early stages ( Figure S3 in Supplementary information). Sustained low muscle and bone uptakes were observed during the entire 60 min scans with standardized uptake values (SUV) of approximate 0.7. As shown in Fig. 7b I-labeled ligands (81 GBq/μmol), the impact of specific activity on pharmacokinetics was studied. In vivo biodistribution of radioactivity after injection of carrier-added [ 125 I]7a with equal specific activity to corresponding [ 18 F]7a (60 GBq/μmol) was conducted in normal ICR mice through the same procedure. As shown in Table S3 in Supplementary information, the brain uptake and clearance profiles (5.39% ID/g at 2 min and 0.37% ID/g at 60 min) were similar to that of the no-carrier-added [ F-labeled chalcone derivatives previously reported by Ono et al. showed a similar difference in the in vivo pharmacokinetics of radioactive components, which the authors attributed to differences in the physicochemical characteristics of the radiometabolites produced in the brain 18, 20 . However, no further investigation was conducted to identify the precise reason for this difference.
To 125 I]12a was so rapid that almost negligible amounts of parent tracers remained at 30 min (8.8% and 6.3%, respectively). The polar and hydrophilic metabolites metabolized by the liver could be absorbed by the intestine and excreted through the urine, in accordance with the biodistribution results. The rapid metabolism in the liver may be another reason for the faster clearance of these compounds from the normal brain. For structurally identical molecules labeled with radioactive isotopes at different positions, the in vivo metabolic pathways were expected to be the same. However, as only radioactive products can be detected with PET/SPECT scanners, different pharmacokinetics of the radioactive components could lead to different imaging results. This dual radiolabeling strategy has been widely used to demonstrate the proposed mechanism of action of drugs 21 . The dual radiolabeled identical benzyloxybenzene derivatives in this study were expected to undergo the same metabolic reactions, generating different radioactive metabolites. Differences in the biochemical characteristics of the radiometabolites including absorption, distribution, metabolism and excretion are responsible for the discrepancy in the pharmacokinetics of the radioactivity.
To further characterize the in vivo Aβ imaging capabilities, we conducted ex vivo autoradiographic studies with [ , 200 μL) was injected intravenously into a Tg mouse (APPswe/PSEN1, male, 27 months old) and an age-matched wild-type mouse (C57BL6, male). Thirty minutes after injection, the brains were removed, weighed and the radioactivity was counted. Then the brains were frozen and sectioned for ex vivo autoradiography. As shown in Fig. 8 , Tg mouse brain exhibited 40% higher radioactivity retention than that of wild-type control mouse at 30 min post-injection. Autoradiographic images displayed clear labeling of Aβ plaques in the Tg mouse brain, and the distributions of radioactive spots correlated well with the amyloid burden as visualized in the same brain sections stained with ThS (Fig. 8b) . Conversely, no such labeling was observed in wild-type mouse brain (Fig. 8c) . These results suggested that [ 125 I]7a penetrated the intact BBB and bound to cerebral Aβ plaques specifically in vivo.
Discussion
Two structurally identical fluorinated and iodinated benzyloxybenzene derivatives were designed for PET/SPECT imaging of Aβ plaques. Molecular docking and 3D-QSAR models predicted excellent binding to Aβ fibers. The high binding affinities were verified by an in vitro competition binding assay using Aβ aggregates with K i values of 19.5 nM and 23.9 nM for 7a and 12a, respectively. Then, the compounds were separately 18 F and 125 I labeled in high radiochemical yields that were suitable for commercial scale production. In vitro autoradiography showed that all of the radiolabeled ligands specifically labeled Aβ plaques on brain sections from AD patients and Tg mice, reflecting the high binding affinities. Methods General Remarks. A structural model of an Aβ fiber (PDB ID: 2LMO) derived from solid state NMR was downloaded from the RCSB Protein Data Bank (www.rcsb.org/pdb). Geometric optimization was performed using Gaussian 09 at the B3LYP/6-31 G and 3-21G levels in the water phase. Molecular docking was performed using AutoDock4.0, and the docking results were graphed with VMD 1.9.1 software. SYBYL-X 1.1 software was used to predict the binding affinities with previously constructed 3D-QSAR models. 6 solutions at room temperature. Mass spectra were acquired with a GCT CA127 Micronass UK instrument. X-ray crystallographic data of compound 12a were collected on a Bruker Smart APEX II diffractometer (Bruker Co., Germany) and deposited at the Cambridge Crystallographic Data Centre as supplementary publication (no. CCDC 1063679). HPLC analysis was performed on a Shimadzu SCL-20 AVP equipped with a Bioscan Flow Count 3200 NaI/ PMT γ-radiation scintillation detector and a SPD-20A UV detector, λ = 254 nm. A Venusil MP C18 reverse phase column (Agela Technologies, 5 μm, 4.6 × 250 mm) was used for separations and purity determinations with a binary gradient system (acetonitrile: water = 80%: 20%) at a 1.0 mL/min flow rate. Fluorescent observation was performed on the Axio Observer Z1 inverted fluorescence microscope (Zeiss, Germany) equipped with a DAPI filter set (excitation, 405 nm). Post-mortem brain sections from an autopsy-confirmed AD subject (64 years old, female) and a control subject (74 years old, male) were acquired from the Chinese Brain Bank. Transgenic mice (APPswe/PSEN1, male) and wild-type mice (C57BL6, male) were purchased from the Institute of Laboratory Animal Science, Chinese Academy of Medical Sciences. Normal ICR mice (20-22 g, male) were used for in vivo biodistribution, dynamic PET/CT and SPECT/CT scans, and biostability experiments. All experiments on mice were performed in accordance with the guidelines approved by the animal care committee of Beijing Normal University and Xiamen University.
Computational methods.
To guarantee the reliability of the docking results and the predicted K i values, all of the molecules were prepared in the same manner as the other benzyloxybenzene derivatives we recently reported. Briefly, molecules 7a and 12a were constructed with GaussView 5.0 based on the X-ray crystal structural of 4 (1-iodo-4-((4-methoxyphenoxy)methyl)benzene). Geometric optimizations were performed in Gaussian 09 (Gaussian 09, Revision C.01, Gaussian, Inc., Wallingford CT, 2010) using B3LYP/3-21G [22] [23] [24] for iodine and B3LYP/6-31G 25 for other atoms in the water phase. A lamarckian genetic algorithm 26 was used to perform docking simulations on Aβ fibers (PDB ID: 2LMO 27 ) with AutoDock4.0 28,29 according to previously described methods. SYBYL-X 1.1 software (Sybyl-X, version 1.1, Tripos Inc., St. Louis, MO, 2010) was used to predict the K i values of 7a and 12a with the previously generated CoMFA and CoMSIA models. As ligand 4 was the template molecule that everything was aligned to in the preceding calculations, it was added to a new database along with 7a and 12a. 7a and 12a were charged and aligned in the same way as the molecules in these models. A spreadsheet was created from the new database, and the K i values were predicted using the previously developed CoMFA and CoMSIA models as the tables referencing the analysis.
Radiolabeling and Biological Evaluation. The radio-iodinated and fluorinated ligands 7a and 12a were prepared from the corresponding tributyltin and tosylate precursors using previously reported procedures 30 . Biological evaluation including the in vitro binding assay using Aβ aggregates, in vitro autoradiography, partition coefficient determination, biodistribution and in vivo biostability studies were all conducted according to previously reported methods 9, 10 . Four normal ICR mice (20-22 g, male) were used for dynamic microPET/CT and microSPECT/CT imaging. The whole-body PET/CT scans were performed using Siemens Inveon device (Siemens Medical Solutions), while SPECT/CT scans were conducted with Mediso nanoScan SPECT/CT scanner (Mediso Medical Imaging System). All mice were anesthetized with 2% isoflurane. Dynamic PET and SPECT scans from 0 to 60 min were started immediately after intravenous injection of [ 18 I]12a (injected dose, 48 MBq), respectively. PET images were reconstructed using three-dimensional ordered subsets expectation maximization (3D OSEM) algorithm, and 3D iterative algorithm was used for SPECT image reconstruction. Time frames for PET imaging were 20 × 60 s and 10 × 240 s, and that for SPECT imaging were 20 × 180 s. Regions of interests (ROIs) were manually drawn on the whole brain, heart, liver, muscle and bone using the CT templates and then transferred to corresponding coregistered PET images. SUVs, injected dose and body weight normalized and decay corrected radioactivity concentration, were calculated for all ROIs. TACs were calculated from this.
Ex vivo autoradiography was performed on a transgenic mouse (APPswe/PSEN1, male, 27 months old) and a wild-type mouse (C57BL6, male, 27 months old). A saline solution (200 μL, 10% EtOH) of 1 mCi of [ USA) for one week. Ex vivo autoradiographic images were obtained using a phosphor imaging system (Cyclone, Packard). Subsequently the same sections were stained with ThS to confirm the presence and location of Aβ plaques.
